6th ICTHIC Preliminary Scientific Program

Friday, April 20th, 2012

2.00 - 2.15 pm Opening: A. Falanga, F.R. Rickles, B. Brenner

2.15 - 4.30 pm **Plenary Session 1: Epidemiology and risk factors of venous thromboembolism**
Chairs: H.A. Liebman (USA), I. Pabinger (Austria)

- Predictive potential of hemostatic biomarkers
C. Ay (*Austria*)
- Update on thrombotic risk stratification
A. Khorana (*USA*)
- Unsuspected PE in cancer patients
M. Monreal (*Spain*)
- Cancer in pregnancy
B. Brenner (*Israel*)
Oral Communications (from abstracts)

5.00 - 7.15 pm **Plenary Session 2: Genomics and proteomics of the hemostatic system in cancer**
Chairs: M.-M. Samama (France), M. Cattaneo (Italy)

- Genetic pathways linking hemostasis and cancer
J. Rak (*Canada*)
- Platelet CLEC-2 in lymphangiogenesis and cancer metastasis
S.P. Watson (*UK*)
- The platelet proteome
W.F. Bahou (*USA*)
- Akt and Ras pathways and modulation of TF expression in glioblastoma
D. Brat (*USA*)
Oral Communications (from abstracts)

7.30 pm **Plenary Lecture: 2nd Simon Karpatkin Memorial Lecture**
Introduction F.R. Rickles (USA)
- Hemostasis, innate immunity and malignancy
J.L. Degen (*USA*)

Saturday, April 21st, 2012

8.15 - 10.30 am **Plenary Session 3 : Bleeding complications in cancer patients**
Chairs: C.M. Kessler (USA), C. Velati (Italy)

- Side effects of anti-angiogenic drugs
F. Rodeghiero (*Italy*)
- Diagnosis and treatment of disseminated intravascular coagulation
C.-H. Toh (*UK*)
- Transfusion issues in the cancer patient
A.B. Federici (*Italy*)
- Acquired hemophilias in cancer
N.S. Key (*USA*)
Oral Communications (from abstracts)

11.00 am - 1.15 pm **Plenary Session 4: Coagulation and cancer progression**
Chairs: M.B. Donati (Italy), R. Labianca (Italy)

- The respective roles of TF isoforms in cancer
H.H. Versteeg (*Netherlands*)
- Heparanase procoagulant activity
Y. Nadir (*Israel*)
- Protein C and cancer
C.A. Spek (*Netherlands*)
- Accounting for death as a competing risk in cancer VTE studies
J.I. Zwicker (*USA*)

Oral Communications (from abstracts)

2.15 - 4.30 pm **Plenary Session 5: Hematological disorders**
Chairs: G.H. Lyman (USA), T. Barbui (Italy)

- Risk and management of thrombosis in multiple myeloma
F.W. Leebeek (*Netherlands*)
- The role of JAK-2 inhibition
A. Rambaldi (Italy)
- Splanchnic vein thrombosis: New risk factors and management
W. Ageno (Italy)
- Heparin-induced thrombocytopenia in cancer
P.M. Sandset (Norway)
Oral Communications (from abstracts)

5.00 - 7.15 pm **Plenary Session 6: Anticoagulants and cancer**
Chairs: S. Schulman (Canada), H.R. Büller (Netherlands)

- New and old anticoagulants in cancer
G. Agnelli (*Italy*)
- Guidelines for antithrombotics in cancer patients
D. Farge-Bancel (*France*)
- Measurement of new oral anticoagulants
J. Harenberg (*Germany*)
- LMWH and survival in lung cancer
S. Noble (*UK*)
Oral Communications (from abstracts)

Sunday, April 22nd, 2012

8.15 - 10.30 am **Plenary Session 7: Platelets and vascular endothelium**
Chairs: C.W. Francis (USA), H. ten Cate (Netherlands)

- The role of thrombomodulin in tumor growth and metastasis
N. Horowitz (*Israel*)
- Endothelial cell activation markers in cancer
A.D. Blann (*UK*)
- Novel functions of tissue factor in thrombosis and in cancer
W. Ruf (*USA*)
- Microparticles and angiogenesis
A. Falanga (*Italy*)
Oral Communications (from abstracts)

11.00 am - 1.15 pm **Plenary Session 8: Prevention and treatment of thrombosis**
Chairs: M.N. Levine (Canada), P. Prandoni (Italy)

- Thromboprophylaxis in the cancer surgical patient
A.K. Kakkar (*UK*)
- Thromboprophylaxis in the cancer medical patient
A.T. Cohen (*UK*)
- Treatment of established thrombotic events
A.Y. Lee (*Canada*)
- Overview of thrombosis and cancer survival
N. Kuderer (*USA*)
Oral Communications (from abstracts)

2.30 - 4.30 pm **Poster Sessions**